# Immunotherapy of Stage III/IV Melanoma Patients

> **NCT00112242** · PHASE1 · COMPLETED · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 39 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Melan-A ELA + Montanide
- **BIOLOGICAL:** Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide
- **BIOLOGICAL:** Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG
- **BIOLOGICAL:** Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG
- **BIOLOGICAL:** Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2

## Key facts

- **NCT ID:** NCT00112242
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112242, "Immunotherapy of Stage III/IV Melanoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00112242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*